ONO-2808 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neurodegenerative Diseases
Conditions
Neurodegenerative Diseases
Trial Timeline
Aug 19, 2020 → Oct 7, 2021
NCT ID
NCT04578028About ONO-2808 + Placebo
ONO-2808 + Placebo is a phase 1 stage product being developed by Ono Pharmaceutical for Neurodegenerative Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT04578028. Target conditions include Neurodegenerative Diseases.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05923866 | Phase 2 | Active |
| NCT04578028 | Phase 1 | Completed |
Competing Products
5 competing products in Neurodegenerative Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Latozinemab | Alector | Phase 3 | 69 |
| Pimavanserin + Placebo | Acadia Pharmaceuticals | Phase 3 | 72 |
| Pimavanserin | Acadia Pharmaceuticals | Approved | 80 |
| Pimavanserin | Acadia Pharmaceuticals | Phase 3 | 72 |
| Blood sampling, skin biopsy, excreta sampling, lumbar puncture | Brain Biotech | Pre-clinical | 15 |